Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
PJ Tacken, IJM De Vries, R Torensma… - Nature Reviews …, 2007 - nature.com
PJ Tacken, IJM De Vries, R Torensma, CG Figdor
Nature Reviews Immunology, 2007•nature.comThe realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses
has stimulated research on harnessing DCs to create more effective vaccines. Early clinical
trials exploring autologous DCs that were loaded with antigens ex vivo to induce T-cell
responses have provided proof of principle. Here, we discuss how direct targeting of
antigens to DC surface receptors in vivo might replace laborious and expensive ex vivo
culturing, and facilitate large-scale application of DC-based vaccination therapies.
has stimulated research on harnessing DCs to create more effective vaccines. Early clinical
trials exploring autologous DCs that were loaded with antigens ex vivo to induce T-cell
responses have provided proof of principle. Here, we discuss how direct targeting of
antigens to DC surface receptors in vivo might replace laborious and expensive ex vivo
culturing, and facilitate large-scale application of DC-based vaccination therapies.
Abstract
The realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses has stimulated research on harnessing DCs to create more effective vaccines. Early clinical trials exploring autologous DCs that were loaded with antigens ex vivo to induce T-cell responses have provided proof of principle. Here, we discuss how direct targeting of antigens to DC surface receptors in vivo might replace laborious and expensive ex vivo culturing, and facilitate large-scale application of DC-based vaccination therapies.
nature.com